Patients received pertuzumab/placebo at 840 mg in cycle 1 and 420 mg in subsequent cycles , and trastuzumab at 8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles ; docetaxel was initiated at 75 mg/m ( 2 ) .